New Delhi: Drug firm Lupin has reported over two-fold increase in consolidated profit after tax at Rs 782 crore for the fourth quarter ended March 31, 2025, driven by new products and operational efficiencies.
The Mumbai-based firm reported a profit after tax (PAT) of Rs 368 crore in the January-March quarter of the 2023-24 fiscal year.
The company's sales increased to Rs 5,562 crore for the fourth quarter ended March 31, 2025, as compared to Rs 4,895 crore in the year-ago period, Lupin Ltd said in a late evening statement on Wednesday.
For FY25, the drug firm reported a PAT of Rs 3,306 crore, up 71 per cent, as compared to Rs 1,936 crore in 2023-24 fiscal.
The company's sales rose to Rs 22,192 crore in the last fiscal, as against Rs 19,656 crore in FY24.
"We are delighted to end the last quarter and the year on a strong note. FY25 was led by strong growth in sales and profitability driven by in-line and new products and consistent improvement in operating margins backed by strong commercial momentum and operational efficiencies," Lupin MD Nilesh Gupta said.
The company is optimistic that this momentum will continue in the year ahead, Gupta said.
The drug firm said its board has recommended a final dividend of Rs 12 per share of the face value of Rs 2 each for the financial year ended March 31, 2025.
Lupin shares were trading 0.06 per cent down at Rs 2,070.70 apiece on the BSE.
Disclaimer: This is a syndicated feed. The article is not edited by the FPJ editorial team.
